"Adjuvants, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
| Descriptor ID |
D000276
|
| MeSH Number(s) |
D27.505.696.477.067
|
| Concept/Terms |
Adjuvants, Immunologic- Adjuvants, Immunologic
- Immunostimulants
- Adjuvant, Immunologic
- Immunologic Adjuvant
- Immunological Adjuvant
- Adjuvant, Immunological
- Immunoactivators
- Immunoadjuvants
- Immunologic Adjuvants
- Immunopotentiators
- Adjuvants, Immunological
- Immunological Adjuvants
|
Below are MeSH descriptors whose meaning is more general than "Adjuvants, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Adjuvants, Immunologic".
This graph shows the total number of publications written about "Adjuvants, Immunologic" by people in this website by year, and whether "Adjuvants, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 3 | 1 | 4 |
| 1997 | 2 | 3 | 5 |
| 1998 | 2 | 3 | 5 |
| 1999 | 1 | 7 | 8 |
| 2000 | 6 | 0 | 6 |
| 2001 | 5 | 2 | 7 |
| 2002 | 8 | 3 | 11 |
| 2003 | 1 | 6 | 7 |
| 2004 | 4 | 3 | 7 |
| 2005 | 3 | 5 | 8 |
| 2006 | 7 | 5 | 12 |
| 2007 | 4 | 2 | 6 |
| 2008 | 3 | 2 | 5 |
| 2009 | 8 | 3 | 11 |
| 2010 | 7 | 4 | 11 |
| 2011 | 3 | 3 | 6 |
| 2012 | 1 | 8 | 9 |
| 2013 | 4 | 3 | 7 |
| 2014 | 2 | 1 | 3 |
| 2015 | 3 | 8 | 11 |
| 2016 | 4 | 5 | 9 |
| 2017 | 5 | 3 | 8 |
| 2018 | 4 | 7 | 11 |
| 2019 | 3 | 4 | 7 |
| 2020 | 2 | 6 | 8 |
| 2021 | 2 | 12 | 14 |
| 2022 | 0 | 8 | 8 |
| 2023 | 0 | 9 | 9 |
| 2024 | 1 | 8 | 9 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adjuvants, Immunologic" by people in Profiles.
-
Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59?. Vaccine. 2025 Feb 15; 47:126702.
-
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens. Vaccine. 2025 Feb 15; 47:126689.
-
Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-na?ve adults. PLoS Negl Trop Dis. 2024 Dec; 18(12):e0012788.
-
The efficacy of egg albumin nanoparticles adjuvanted Clostridium perfringens type D toxoid vaccine in rabbits. Braz J Microbiol. 2025 Mar; 56(1):665-674.
-
Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization. Front Immunol. 2024; 15:1480976.
-
Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Gu?rin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group. Eur Urol Oncol. 2025 Feb; 8(1):216-229.
-
Intranasal sensitization model of alopecia areata using pertussis toxin as adjuvant. Front Immunol. 2024; 15:1469424.
-
Predicting Response to Intravesical Bacillus Calmette-Gu?rin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center Cohort. J Urol. 2025 Feb; 213(2):192-204.
-
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. BJU Int. 2025 Feb; 135(2):260-268.
-
Bladder-sparing Therapy for Bacillus Calmette-Gu?rin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. Eur Urol. 2024 Dec; 86(6):516-527.